Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Weiguo Liu

Scott D Edmondson

Wanying Sun

Amjad Ali

Santhosh Francis Neelamkavil

Ying-Duo Gao

Anthony K Ogawa

Sung-Sau So

Zhuyan Guo

Rongze Kuang

Eric Mertz

Lihu Yang

Xianhai Huang

Haifeng Tang

Harold B Wood

Alan W Hruza

Linda Brockunier

Tesfaye Biftu

Paul E Finke

Jinlong Jiang

Joey Lee Methot

Fa-Xiang Ding

Songnian Lin

Yan Guo

Yeon-Hee Lim

Yu Jiang

Peter H Fuller

Blair T Lapointe

Hakan Gunaydin

Andrew William Stamford

Mark D Erion

Alexander Pasternak

Barbara A Pio

Dong-Ming Shen

Jianming Bao

F Anthony Romero

Feroze Ujjainwalla

Ling Tong

Younong Yu

Ping Liu

Dooseop Kim

Thomas H Graham

Solomon D Kattar

Shawn P Walsh

Cheng Zhu

Helen Y Chen

Rajan Anand

Blaise S Lippa

Heping Wu

Yi Zang

Jiafang He

Gui-Bai Liang

Remond Moningka

Rudrajit Mal

Weidong Pan

Joseph Leslie Duffy

Jiayi Xu

Min K Park

Vladimir Simov

Hongwu Wang

Zahid Hussain

J Michael Ellis

David Annunziato Candito

John Acton

Christopher W Plummer

Xibin Liao

Wei Zhou

Nancy J Kevin

Tingting Yu

Deyou Sha

Feng Ye

Thomas A Bara

Chunsing Li

Edward C Sherer

Debra L Ondeyka

Sriram Tyagarajan

Bart Harper

Meng Yang

Ellen K Vande Bunte

Reynalda Keh Dejesus

Revathi Reddy Katipally

Min Ge

Gioconda V Gallo-Etienne

Anjan Chakrabarti

Puneet Kumar

Joanna L Chen

Michael A Plotkin

Anmol Gulati

Aaron Zwicker

Hiroki Sone

Jon Christian Baber

Patrick Shao

Ryan Wing-Kun Chau

Andrew F Nolting

Mitchell Henry Keylor

Fiona Wai Yu Lau

Jing Zhang

John Bawiec

Bhuamik Pandya

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. 

Chromane monobactam compounds for the treatment of bacterial infections

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, X, Y, Rand Rare as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved. 

Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved. 

Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, L, M, W, X, Y, Z, Rand Rare as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds. 

Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein. 

Factor XIA inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor Xla inhibitors

Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.

Substituted bicyclic amines for the treatment of diabetes

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

Growing community of inventors

Princeton, NJ, United States of America

Weiguo Liu